Funding

Exciva

Germany · Biotech

Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease

Visit exciva.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series B€51MAndera Partners — Role not disclosedCarma Fund — Role not disclosedEQT Life Sciences — Role not disclosedFountain Healthcare Partners — Role not disclosedGimv — Role not disclosedLBBW — Role not disclosedLifeArc — Role not disclosedLSP Dementia Fund — Role not disclosedModi Ventures — Role not disclosed

Investors

Andera PartnersSeries BCarma FundSeries BEQT Life SciencesSeries BFountain Healthcare PartnersSeries BGimvSeries BLBBWSeries BLifeArcSeries BLSP Dementia FundSeries BModi VenturesSeries B

Coverage

Jan 20, 2026Exciva · Series B

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesexciva.com ↗